Anti-hIL-28b Neutralizing mAb

Neutralizing monoclonal antibody against human interleukin 28B

Neutralizing monoclonal antibody against human IL-28B

Anti-hIL-28b-IgG (clone 18F4) is a monoclonal antibody (mAb) specific for human interleukin 28B (hIL-28B). It is produced in hybridomas and purified by affinity chromatography. This antibody has been selected for its ability to efficiently neutralize the biological activity of hIL-28B. IL-28B (also known as interferon lambda 3) is a member of the type III interferon (IFN lambda) cytokine family that exhibits several common features with type I IFNs: antiviral activity and antitumor activity [1, 2]. 

More details

Key features:

• A potent and specific neutralizing mAb against hIL-28B
• Provided azide-free
• Each lot is functionally tested

References:

1. Donnelly RP. & Kotenko SV., 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 30(8):555-64.
2. Li M. et al., 2009. Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol., 86:23-32.

Figures

Anti-hIL-28b-IgG is a potent neutralization antibody. Increasing concentrations of Anti-hIL-28b-IgG were incubated for 30 minutes with the recombinant cytokine hIL-28b (1 ng/ml) prior to the addition of HEK-Blue™ IFN-λ cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are presented as percentage of neutralization (mean).

Specifications

Target: natural and recombinant human IL-28B

Specificity: No cross-reactivity with human IL-28A, mouse IL-28A or mouse IL-28B.

Clone: 18F4

Isotype: Mouse IgG1, kappa

Control: Mouse IgG1 Control

Immunogen: Human IL-28B protein expressed in Swiss mice following DNA immunization

Formulation: 0.2 µm filtered solution in Tris HCl buffer with saccharose, glycine and stabilizing agents

Tested applications: Blocking & Neutralisation

Quality control:

• This product has been validated for neutralization using cellular assays.
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Contents

• 3 x 100 μg purified anti-hIL-28b-IgG antibody, provided azide-free and lyophilized

Product is shipped at room temperature.

Store lyophilized antibody at -20 °C.

Details

The IFN-λ family is essential to the antiviral response at epithelial barriers [1,2]. In humans, this family comprises four distinct proteins called IFN-λ1 (interleukin-29, IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and the poorly secreted IFN-λ4. In mice, two functional orthologs (IL-28A and IL-28B) have been described. IFN-λs are produced when a viral infection is sensed by pattern recognition receptors. IFN-λs bind to a heterodimeric receptor formed by the assembly of IFNLR1 and IL10Rβ. This leads to the recruitment of the Janus kinases, JAK1 and TyK2, and phosphorylation of STAT1 and STAT2, which then dimerize and interact with IFN regulatory factor 9 (IRF9), forming the ISGF3 complex. ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoters of IFN-stimulated genes (ISG) to regulate their expression.

1. Lazear HM. et al., 2015. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity. 43(1):15-28.
2. Lee S. & Baldridge MT., 2017. Interferon- Lambda: A Potent Regulator of Intestinal Viral Infections. Front Immunol. 8:749.